Elevance Health Inc (ELV · NYSE)

ELV · MARKET VIEW

Market view · as of Oct 5, 2026

Revenue (TTM)
$201.11B
+1.4% YoY
Gross margin
26.0%
EPS (latest q)
$7.45
vs $6.18 est · beat
52-wk position
74.0%
-9.1% vs 52w high · -6.5% 1mo

Price (last ~year)

Elevance Health shares closed at $386.43, up 1.2% on the day but down 6.5% over the past month, with an RSI of 13 signaling deeply oversold conditions despite trading 6.5% above its 200-day moving average. The company beat earnings estimates in all four of its most recent quarters, including Q2 2026 EPS of $7.45 versus $6.18 expected, though earnings fell 13.1% year over year on modest 1.4% revenue growth to $201.11B TTM. Leverage stands at 3.7x debt/EBITDA with $10.23B in cash, and quarterly operating cash flow of $1.91B against $287.0M capex left $1.63B in free cash flow. BofA raised its price target to $480 ahead of the Q3 report, above the $451.38 analyst consensus.

Valuation

Market cap
$83.80B
P/E
17.09
PEG
1.304
P/B
1.926
P/S
0.417
Beta
0.696
Analyst target
$451.38

Quality & returns

Gross margin
26.0%
Operating margin
4.6%
Profit margin
2.5%
ROE
11.1%
ROA
3.8%

Price movement

Last
$386.43
1-month
-6.5%
3-month
-7.7%
RSI (14)
13
vs SMA200
+6.5%
52-wk position
74.0% -9.1% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$50.47B$2.06B$1.46B$2.10B
2026-03-31$50.18B$2.66B$1.76B$2.77B
2025-12-31$49.75B$581.0M$547.0M$987.0M
2025-09-30$50.71B$1.76B$1.19B$2.14B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots